{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:59:15Z","timestamp":1790801955111,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH117431"],"award-info":[{"award-number":["R01MH117431"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["2I01CX000139"],"award-info":[{"award-number":["2I01CX000139"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41380-024-02433-8","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T04:46:59Z","timestamp":1707367619000},"page":"1528-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics"],"prefix":"10.1038","volume":"29","author":[{"given":"M. D.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-3839","authenticated-orcid":false,"given":"S. S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Le-Niculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"MacKie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bhagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Roseberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-3138","authenticated-orcid":false,"given":"O. K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. D.","family":"Dainton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-5789","authenticated-orcid":false,"given":"A. B.","family":"Niculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"2433_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41386-021-01183-3","volume":"47","author":"H Le-Niculescu","year":"2022","unstructured":"Le-Niculescu H, Niculescu AB. Precision medicine in psychiatry: biomarkers to the forefront. Neuropsychopharmacology. 2022;47:422\u20133.","journal-title":"Neuropsychopharmacology"},{"key":"2433_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/mp.2013.95","volume":"18","author":"H Le-Niculescu","year":"2013","unstructured":"Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N, et al. Discovery and validation of blood biomarkers for suicidality. Mol Psychiatry. 2013;18:1249\u201364.","journal-title":"Mol Psychiatry"},{"key":"2433_CR3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/mp.2015.112","volume":"20","author":"AB Niculescu","year":"2015","unstructured":"Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, et al. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. Mol psychiatry. 2015;20:1266\u201385.","journal-title":"Mol psychiatry"},{"key":"2433_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/mp.2016.31","volume":"21","author":"DF Levey","year":"2016","unstructured":"Levey DF, Niculescu EM, Le-Niculescu H, Dainton HL, Phalen PL, Ladd TB, et al. Towards understanding and predicting suicidality in women: biomarkers and clinical risk assessment. Mol Psychiatry. 2016;21:768\u201385.","journal-title":"Mol Psychiatry"},{"key":"2433_CR5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/mp.2017.128","volume":"22","author":"AB Niculescu","year":"2017","unstructured":"Niculescu AB, Le-Niculescu H, Levey DF, Phalen PL, Dainton HL, Roseberry K, et al. Precision medicine for suicidality: from universality to subtypes and personalization. Mol Psychiatry. 2017;22:1250\u201373.","journal-title":"Mol Psychiatry"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1021\/bi8019355","volume":"48","author":"S Kilka","year":"2009","unstructured":"Kilka S, Erdmann F, Migdoll A, Fischer G, Weiwad M. The proline-rich N-terminal sequence of calcineurin Abeta determines substrate binding. Biochemistry. 2009;48:1900\u201310.","journal-title":"Biochemistry"},{"key":"2433_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cr.2016.14","volume":"26","author":"SJ Li","year":"2016","unstructured":"Li SJ, Wang J, Ma L, Lu C, Wang J, Wu JW, et al. Cooperative autoinhibition and multi-level activation mechanisms of calcineurin. Cell Res. 2016;26:336\u201349.","journal-title":"Cell Res"},{"key":"2433_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biopsych.2022.11.005","volume":"94","author":"E Parnell","year":"2023","unstructured":"Parnell E, Culotta L, Forrest MP, Jalloul HA, Eckman BL, Loizzo DD, et al. Excitatory dysfunction drives network and calcium handling deficits in 16p11.2 duplication schizophrenia induced pluripotent stem cell-derived neurons. Biol Psychiatry. 2023;94:153\u201363.","journal-title":"Biol Psychiatry"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1073\/pnas.081071198","volume":"98","author":"Y Hakak","year":"2001","unstructured":"Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 2001;98:4746\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2433_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2019.05.011","volume":"209","author":"DJ Leirer","year":"2019","unstructured":"Leirer DJ, Iyegbe CO, Di Forti M, Patel H, Carra E, Fraietta S, et al. Differential gene expression analysis in blood of first episode psychosis patients. Schizophr Res. 2019;209:88\u201397.","journal-title":"Schizophr Res"},{"key":"2433_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.biopsych.2011.02.033","volume":"70","author":"CM Liu","year":"2011","unstructured":"Liu CM, Fann CS, Chen CY, Liu YL, Oyang YJ, Yang WC, et al. ANXA7, PPP3CB, DNAJC9, and ZMYND17 genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function. Biol Psychiatry. 2011;70:51\u20138.","journal-title":"Biol Psychiatry"},{"key":"2433_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.schres.2016.02.012","volume":"172","author":"DA Forero","year":"2016","unstructured":"Forero DA, Herteleer L, De Zutter S, Norrback KF, Nilsson LG, Adolfsson R, et al. A network of synaptic genes associated with schizophrenia and bipolar disorder. Schizophr Res. 2016;172:68\u201374.","journal-title":"Schizophr Res"},{"key":"2433_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nn.4181","volume":"19","author":"AE Jaffe","year":"2016","unstructured":"Jaffe AE, Gao Y, Deep-Soboslay A, Tao R, Hyde TM, Weinberger DR, et al. Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nat Neurosci. 2016;19:40\u20137.","journal-title":"Nat Neurosci"},{"key":"2433_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09915","volume":"473","author":"KJ Brennand","year":"2011","unstructured":"Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221\u20135.","journal-title":"Nature"},{"key":"2433_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.24","volume":"1","author":"K Mozhui","year":"2011","unstructured":"Mozhui K, Wang X, Chen J, Mulligan MK, Li Z, Ingles J, et al. Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes. Transl Psychiatry. 2011;1:e25.","journal-title":"Transl Psychiatry"},{"key":"2433_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/mp.2014.29","volume":"19","author":"SE McCarthy","year":"2014","unstructured":"McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry. 2014;19:652\u20138.","journal-title":"Mol Psychiatry"},{"key":"2433_CR17","doi-asserted-by":"publisher","first-page":"144913","DOI":"10.1016\/j.gene.2020.144913","volume":"756","author":"F Ozsoy","year":"2020","unstructured":"Ozsoy F, Karakus NB, Yigit S, Kulu M. Effect of AUTS2 gene rs6943555 variant in male patients with schizophrenia in a Turkish population. Gene. 2020;756:144913.","journal-title":"Gene"},{"key":"2433_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tig.2013.08.001","volume":"29","author":"N Oksenberg","year":"2013","unstructured":"Oksenberg N, Ahituv N. The role of AUTS2 in neurodevelopment and human evolution. Trends Genet. 2013;29:600\u20138.","journal-title":"Trends Genet"},{"key":"2433_CR19","doi-asserted-by":"crossref","unstructured":"Pisanu C, Merkouri Papadima E, Melis C, Congiu D, Loizedda A, Orru N et al. Whole genome expression analyses of miRNAs and mRNAs suggest the involvement of miR-320a and miR-155-3p and their targeted genes in lithium response in bipolar disorder. Int J Mol Sci. 2019;20:6040.","DOI":"10.3390\/ijms20236040"},{"key":"2433_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/toxsci\/kfv094","volume":"146","author":"SH Schulpen","year":"2015","unstructured":"Schulpen SH, Pennings JL, Piersma AH. Gene expression regulation and pathway analysis after valproic acid and carbamazepine exposure in a human embryonic stem cell-based neurodevelopmental toxicity assay. Toxicol Sci. 2015;146:311\u201320.","journal-title":"Toxicol Sci"},{"key":"2433_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","volume":"173","author":"TS Stroup","year":"2016","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173:166\u201373.","journal-title":"Am J Psychiatry"},{"key":"2433_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1176\/ajp.136.3.283","volume":"136","author":"PE Alexander","year":"1979","unstructured":"Alexander PE, van Kammen DP, Bunney WE Jr. Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry. 1979;136:283\u20137.","journal-title":"Am J Psychiatry"},{"key":"2433_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1192\/bjp.144.1.64","volume":"144","author":"FP Zemlan","year":"1984","unstructured":"Zemlan FP, Hirschowitz J, Sautter FJ, Garver DL. Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry. 1984;144:64\u20139.","journal-title":"Br J Psychiatry"},{"key":"2433_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0924-9338(98)80027-8","volume":"13","author":"M Moldavsky","year":"1998","unstructured":"Moldavsky M, Stein D, Benatov R, Sirota P, Elizur A, Matzner Y, et al. Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder. Eur Psychiatry. 1998;13:104\u20136.","journal-title":"Eur Psychiatry"},{"key":"2433_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/acps.13498","volume":"147","author":"A Puranen","year":"2023","unstructured":"Puranen A, Koponen M, Lahteenvuo M, Tanskanen A, Tiihonen J, Taipale H. Real-world effectiveness of mood stabilizer use in schizophrenia. Acta Psychiatr Scand. 2023;147:257\u201366.","journal-title":"Acta Psychiatr Scand"},{"key":"2433_CR26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1176\/appi.ajp.157.11.1727","volume":"157","author":"JA Lieberman","year":"2000","unstructured":"Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry. 2000;157:1727\u201330.","journal-title":"Am J Psychiatry"},{"key":"2433_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","volume":"148","author":"R Chen","year":"2012","unstructured":"Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293\u2013307.","journal-title":"Cell"},{"key":"2433_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41380-018-0345-5","volume":"24","author":"AB Niculescu","year":"2019","unstructured":"Niculescu AB, Le-Niculescu H, Levey DF, Roseberry K, Soe KC, Rogers J, et al. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019;24:501\u201322.","journal-title":"Mol Psychiatry"},{"key":"2433_CR29","doi-asserted-by":"crossref","unstructured":"Le-Niculescu H, Roseberry K, Levey DF, Rogers J, Kosary K, Prabha S et al. Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs. Mol Psychiatry. 2020;25:918\u201338.","DOI":"10.1038\/s41380-019-0370-z"},{"key":"2433_CR30","doi-asserted-by":"crossref","unstructured":"Niculescu AB, Le-Niculescu H, Roseberry K, Wang S, Hart J, Kaur A et al. Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2020;25:1651\u201372.","DOI":"10.1038\/s41380-019-0602-2"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41380-021-01061-w","volume":"26","author":"H Le-Niculescu","year":"2021","unstructured":"Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, et al. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2021;26:2776\u2013804.","journal-title":"Mol Psychiatry"},{"key":"2433_CR32","doi-asserted-by":"crossref","unstructured":"Roseberry K, Le-Niculescu H, Levey DF, Bhagar R, Soe K, Rogers J, et al. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2023;28:2894\u2013912.","DOI":"10.1038\/s41380-023-01998-0"},{"key":"2433_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajmg.b.30481","volume":"144B","author":"H Le-Niculescu","year":"2007","unstructured":"Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE, et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:129\u201358.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2433_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/mp.2008.11","volume":"14","author":"H Le-Niculescu","year":"2009","unstructured":"Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry. 2009;14:156\u201374.","journal-title":"Mol Psychiatry"},{"key":"2433_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy V, Pardinas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502\u20138.","journal-title":"Nature"},{"key":"2433_CR36","doi-asserted-by":"crossref","unstructured":"Jaholkowski P, Hindley GFL, Shadrin AA, Tesfaye M, Bahrami S, Nerhus M et al. Genome-wide Association Analysis of Schizophrenia and Vitamin D Levels Shows Shared Genetic Architecture and Identifies Novel Risk Loci. Schizophr Bull. 2023;49:1654\u201364.","DOI":"10.1093\/schbul\/sbad063"},{"key":"2433_CR37","doi-asserted-by":"publisher","first-page":"e2446","DOI":"10.1002\/brb3.2446","volume":"12","author":"H Hjelmervik","year":"2022","unstructured":"Hjelmervik H, Craven AR, Johnsen E, Kompus K, Bless JJ, Sinkeviciute I, et al. Negative valence of hallucinatory voices as predictor of cortical glutamatergic metabolite levels in schizophrenia patients. Brain Behav. 2022;12:e2446.","journal-title":"Brain Behav"},{"key":"2433_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.celrep.2017.12.044","volume":"22","author":"XF Zhao","year":"2018","unstructured":"Zhao XF, Kohen R, Parent R, Duan Y, Fisher GL, Korn MJ, et al. PlexinA2 forward signaling through Rap1 GTPases regulates dentate gyrus development and schizophrenia-like behaviors. Cell Rep. 2018;22:456\u201370.","journal-title":"Cell Rep."},{"key":"2433_CR39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1017\/S0033291706008191","volume":"36","author":"EQ Wu","year":"2006","unstructured":"Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36:1535\u201340.","journal-title":"Psychol Med"},{"key":"2433_CR40","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1017\/S2045796019000891","volume":"29","author":"H He","year":"2020","unstructured":"He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020;29:e91.","journal-title":"Epidemiol Psychiatr Sci"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02433-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:06:40Z","timestamp":1718892400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02433-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02433-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ABN is listed as inventor on a patent application filed by Indiana University. ABN and AS are co-founders, SMK is a consultant, and SSG is a part-time employee of MindX Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}